The QuANTUM-First phase 3 trial studied quizartinib combined with induction and consolidation chemotherapy, versus placebo combined with induction and consolidation chemotherapy, in newly diagnosed FLT-ITD-positive AML. This evidence concerns the gene FLT1 and acute myeloid leukemia.